New immune drug tested in tough pancreatic cancer cases
NCT ID NCT05304936
Summary
This study tested a new drug called HCW9218 in people with advanced pancreatic cancer that had worsened despite standard treatment. The main goals were to find a safe dose and see if the drug could help control the cancer. It was a small, early-stage trial involving 21 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
HonorHealth
Scottsdale, Arizona, 85258, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
National Institute of Health/ National Cancer Institute
Bethesda, Maryland, 20892, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.